Tiffany K Weidner1, John T Kidwell1, David A Etzioni2,3, Lindsey R Sangaralingham2, Holly K Van Houten2, Dennis Asante2, Molly Moore Jeffery2, Nilay Shah2,4, Nabil Wasif5,6. 1. Department of General Surgery, Mayo Clinic, 5777 E Mayo Blvd., Phoenix, AZ, 85054, USA. 2. Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. 3. Division of Colorectal Surgery, Mayo Clinic, Phoenix, AZ, USA. 4. OptumLabs, Cambridge, MA, USA. 5. Department of General Surgery, Mayo Clinic, 5777 E Mayo Blvd., Phoenix, AZ, 85054, USA. wasif.nabil@mayo.edu. 6. Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. wasif.nabil@mayo.edu.
Abstract
PURPOSE: We assessed emergency department (ED) utilization in patients with colorectal cancer to identify factors associated with ED visits and subsequent admission, as well as identify a high-risk subset of patients that could be targeted to reduce ED visits. METHODS: Data from Optum Labs Data Warehouse, a national administrative claims database, was retrospectively analyzed to identify patients with colorectal cancer from 2008 to 2014. Multivariable logistic regression was used to identify factors associated with ED visits and ED "super-users" (3+ visits). Repeated measures analysis was used to model ED visits resulting in hospitalization as a logistic regression based on treatments 30 days prior to ED visit. RESULTS: Of 13,466 patients with colorectal cancer, 7440 (55.2%) had at least one ED visit within 12 months of diagnosis. Factors associated with having an ED visit included non-white race, advancing age, increased comorbidities, and receipt of chemotherapy or radiation. 69.2% of patients who visited the ED were admitted to the hospital. A group of 1834 "super-users" comprised 13.6% of our population yet accounted for 52.1% of the total number of ED visits and 32.3% of admissions. CONCLUSIONS: Over half of privately insured patients undergoing treatment for colorectal cancer will visit the ED within 12 months of diagnosis. Within this group, we identify common factors for a high-risk subset of patients with three or more ED visits who account for over half of all ED visits and a third of all admissions. These patients could potentially be targeted with alternative management strategies in the outpatient setting.
PURPOSE: We assessed emergency department (ED) utilization in patients with colorectal cancer to identify factors associated with ED visits and subsequent admission, as well as identify a high-risk subset of patients that could be targeted to reduce ED visits. METHODS: Data from Optum Labs Data Warehouse, a national administrative claims database, was retrospectively analyzed to identify patients with colorectal cancer from 2008 to 2014. Multivariable logistic regression was used to identify factors associated with ED visits and ED "super-users" (3+ visits). Repeated measures analysis was used to model ED visits resulting in hospitalization as a logistic regression based on treatments 30 days prior to ED visit. RESULTS: Of 13,466 patients with colorectal cancer, 7440 (55.2%) had at least one ED visit within 12 months of diagnosis. Factors associated with having an ED visit included non-white race, advancing age, increased comorbidities, and receipt of chemotherapy or radiation. 69.2% of patients who visited the ED were admitted to the hospital. A group of 1834 "super-users" comprised 13.6% of our population yet accounted for 52.1% of the total number of ED visits and 32.3% of admissions. CONCLUSIONS: Over half of privately insured patients undergoing treatment for colorectal cancer will visit the ED within 12 months of diagnosis. Within this group, we identify common factors for a high-risk subset of patients with three or more ED visits who account for over half of all ED visits and a third of all admissions. These patients could potentially be targeted with alternative management strategies in the outpatient setting.
Authors: D K McClish; L Penberthy; M Whittemore; C Newschaffer; D Woolard; C E Desch; S Retchin Journal: Am J Epidemiol Date: 1997-02-01 Impact factor: 4.897
Authors: Al B Benson; Alan P Venook; Lynette Cederquist; Emily Chan; Yi-Jen Chen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Peter C Enzinger; Alessandro Fichera; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Christina S Wu; Kristina M Gregory; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2017-03 Impact factor: 11.908
Authors: Paul J Wallace; Nilay D Shah; Taylor Dennen; Paul A Bleicher; Paul D Bleicher; William H Crown Journal: Health Aff (Millwood) Date: 2014-07 Impact factor: 6.301